B lymphocytes express multiple TLRs that regulate their cytokine production. We investigated the effect of TLR4 and TLR9 activation on receptor activator of NF-kB ligand (RANKL) expression by rat spleen B cells. Splenocytes or purified spleen B cells from Rowett rats were cultured with TLR4 ligand Escherichia coli LPS and/or TLR9 ligand CpG-oligodeoxynucleotide (CpG-ODN) for 2 days. RANKL mRNA expression and the percentage of RANKL-positive B cells were increased in rat splenocytes challenged by E. coli LPS alone. The increases were less pronounced when cells were treated with both CpG-ODN and E. coli LPS. Microarray analysis showed that expressions of multiple cyclin-dependent kinase (CDK) pathway-related genes were up-regulated only in cells treated with both E. coli LPS and CpG-ODN. This study suggests that CpG-ODN inhibits LPS-induced RANKL expression in rat B cells via regulation of the CDK pathway.Key words B lymphocytes, immune response, RANK ligand, Toll-like receptor.Not only in immune defense against microbial insults, but also in bone pathogenesis, immune responses to gramnegative bacterial infections, including periodontitis, involve activated B lymphocytes (1-3). Our studies and those of others have demonstrated that B lymphocytes produce RANKL in bone resorptive lesions of periodontal disease (3-5), and the excess RANKL shifts the balance of bone metabolism towards catabolism, resulting in pathological bone resorption (6). In order to design interventional strategies targeting amelioration of bone resorption in such situations, it is essential to clarify the mechanism(s) of control of B-cell-associated bone pathogenesis. While TLR signaling pathways play an important role in regulating B cell functions (7,8), including cytokine production, phagocytosis, and apoptosis (9), little is known about TLR signaling in the control of B cell-mediated bone pathogenesis.Although RANKL up-regulation is usually considered to be induced by pro-inflammatory cytokines, LPS from gram-negative bacteria can also directly increase amounts of RANKL mRNA in osteoblast-and osteoclast-lineage cells (10,11). Studies have demonstrated that activation of TLR2 or TLR4 results in RANKL-dependent osteoclastogenesis in rheumatoid arthritis synovium (12, 13). In addition, upon TLR9 ligation CpG-ODN reportedly induces osteoblast osteoclastogenic activity (14). However, other studies have shown that activation of TLRs (specifically TLR4 and TLR9) in early osteoclast precursors results in inhibition of RANKL-induced osteoclast differentiation via IL-12 (15). In human osteoclast precursor cell culture models, TLR ligands inhibit RANK expression by down-regulating cell surface expression of macrophage colony-stimulating factor receptor c-Fms, thereby List of Abbreviations: 7-AAD, 7-amino-actinomycin D; CDK, cyclin-dependent kinase; CDKI, cyclin-dependent kinase inhibitor; CpG-ODN, CpGoligodeoxynucleotide; EGFR, epidermal growth factor receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; NF-kB, nuclear factor kappalight-ch...